Global DNA hypomethylation in prostate cancer development and progression: A systematic review

Prostate Cancer and Prostatic Diseases

Volumn 18, Issue 1, 2015, Pages 1-12

  Zelic, R ^a   Fiano, V ^a   Grasso, C ^a   Zugna, D ^a   Pettersson, A ^b   Gillio Tos, A ^a   Merletti, F ^a   Richiardi, L ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL ASSESSMENT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISTANT METASTASIS; DNA METHYLATION; HUMAN; PROSTATE CANCER; PYROSEQUENCING; QUANTITATIVE ANALYSIS; REVIEW; SYSTEMATIC REVIEW; CANCER GRADING; DISEASE COURSE; GENETICS; LONG INTERSPERSED REPEAT; MALE; MEDLINE; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; TUMOR RECURRENCE;

DISEASE PROGRESSION; DNA METHYLATION; HUMANS; LONG INTERSPERSED NUCLEOTIDE ELEMENTS; MALE; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATIC NEOPLASMS; PUBMED;

EID: 84922623572     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2014.45     Document Type: Review

References (79)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. International Agency for Research on Cancer: Lyon, France, 2013; Available from http://globocan.iarc.fr. accessed on 22 January 2014.
2. Moyer VA. On behalf of the U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157: 120-134.
3. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71.
4. Schulz WA, Hoffmann MJ. Epigenetic mechanisms in the biology of prostate cancer. Semin Cancer Biol 2009; 19: 172-180.
5. Yang B, Bhusari S, Kueck J, Weeratunga P, Wagner J, Leverson G et al. Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer. Neoplasia 2013; 4: 399-408.
6. Dobosy JR, Roberts JL, Fu VX, Jarrard DF. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol 2007; 177: 822-831.
7. Jeronimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ et al. Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol 2011; 60: 753-766.
8. Albany C, Alva AS, Aparicio AM, Singal R, Yellapragada S, Sonpavde G et al. Epigenetics in prostate cancer. Prostate cancer 2011; 2011: 580318.
9. Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 2005; 97: 103-115.
10. Brait M, Sidransky D. Cancer epigenetics: above and beyond. Toxicol Mech Methods 2011; 21: 275-288.
11. Grønbaek K, Treppendahl M, Asmar F, Guldberg P. Epigenetic changes in cancer as potential targets for prophylaxis and maintenance therapy. Basic Clin Pharmacol Toxicol 2008; 103: 389-396.
12. Singh PK, Campbell MJ. The interactions of microRNA and epigenetic modifications in prostate cancer. Cancers 2013; 5: 998-1019.
13. Willard SS, Koochekpour S. Regulators of gene expression as biomarkers for prostate cancer. Am J Cancer Res 2012; 2: 620-657.
14. Ellis L, Atadja PW, Johnstone RW. Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther 2009; 8: 1409-1420.
15. Li XQ, Guo YY, De W. DNA methylation and microRNAs in cancer. World J Gastroenterol 2012; 18: 882-888.
16. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-428.
17. Mahapatra S, Klee EW, Young CY, Sun Z, Jimenez RE, Klee GG et al. Global methylation profiling for risk prediction of prostate cancer. Clin Cancer Res 2012; 18: 2882-2895.
18. Majumdar S, Buckles E, Estrada J, Koochekpour S. Aberrant DNA methylation and prostate cancer. Curr Genomics 2011; 12: 486-505.
19. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004; 13: 4632-4642.
20. Perry AS, Foley R, Woodson K, Lawler M. The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr Relat Cancer 2006; 13: 357-377.
21. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128: 683-692.
22. Esteller M. Aberrant DNA methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol 2005; 45: 629-656.
23. Ahmed H. Promoter methylation in prostate cancer and its application for the early detection of prostate cancer using serum and urine samples. Biomark Cancer 2010; 2010: 17-33.
24. Delgado-Cruzata L, Hruby GW, Gonzalez K, McKiernan J, Benson MC, Santella RM et al. DNA methylation changes correlate with Gleason score and tumor stage in prostate cancer. DNA Cell Biol 2012; 31: 187-192.
25. Koochekpour S. DNA methylome and the complexity of discovering prostate cancer biomarkers. Asian J Androl 2011; 13: 661-662.
26. Vanaja DK, Ehrlich M, Van den Boom D, Cheville JC, Karnes RJ, Tindall DJ et al. Hypermethylation of genes for diagnosis and risk strati fication of prostate cancer. Cancer Invest 2009; 27: 549-560.
27. Park JY. Promoter hypermethylation in prostate cancer. Cancer Control 2010; 17: 245-255.
28. Van Neste L, Herman JG, Otto G, Bigley JW, Epstein JI, Van Criekinge W. The epigenetic promise for prostate cancer diagnosis. Prostate 2012; 72: 1248-1261.
29. Aschelter AM, Giacinti S, Caporello P, Marchetti P. Genomic and epigenomic alterations in prostate cancer. Front Endocrin 2012; 3: 128.
30. Li LC. Epigenetics of prostate cancer. Front Biosci 2007; 12: 3377-3397.
31. Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zochbauer-Muller S, Farinas AJ et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002; 8: 514-519.
32. Phé V, Cussenot O, Roupret M. Methylated genes as potential biomarkers in prostate cancer. BJU Int 2010; 105: 1364-1370.
33. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-2054.
34. Jeronimo C, Henrique R, Hoque MO, Mambo E, Ribeiro FR, Varzim G et al. A quantitative promoter methylation profile of prostate cancer. Clin Cancer Res 2004; 10: 8472-8478.
35. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 2004; 64: 1975-1986.
36. Gama-Sosa MA, Slagel VA, Trewyn RW, Oxenhandler R, Kuo KC, Gehrke CW et al. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res 1983; 11: 6883-6894.
37. Richiardi L, Fiano V, Vizzini L, De Marco L, Delsedime L, Akre O et al. Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J Clin Oncol 2009; 27: 3161-3168.
38. Richiardi L, Fiano V, Grasso C, Zugna D, Delsedime L, Gillio-Tos A et al. Methylation of APC and GSTP1 in non-neoplastic tissue adjacent to prostate tumour and mortality from prostate cancer. PLoS One 2013; 8: e68162.
39. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301: 89-92.
40. Kim YI, Giuliano A, Hatch KD, Schneider A, Nour MA, Dallal GE et al. Global DNA hypomethylation increases progressively in cervical dysplasia and carcinoma. Cancer 1994; 74: 893-899.
41. Ehrlich M. DNA hypomethylation in cancer cells. Epigenomics 2009; 1: 239-259.
42. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. Biochim Biophys Acta 2007; 1775: 138-162.
43. Narayan A, Ji W, Zhang XY, Marrogi A, Graff JR, Baylin SB et al. Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int J Cancer 1998; 77: 833-838.
44. Qu G, Dubeau L, Narayan A, Yu M, Ehrlich M. Satellite DNA hypomethylation vs overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential. Mut Res 1999; 423: 91-101.
45. Florl AR, Steinhoff C, Muller M, Seifert HH, Hader C, Engers R et al. Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. Br J Cancer 2004; 91: 985-994.
46. Kim MJ, White-Cross JA, Shen L, Issa JP, Rashid A. Hypomethylation of long interspersed nuclear element-1 in hepatocellular carcinomas. Mod Pathol 2009; 22: 442-449.
47. Rodriguez J, Vives L, Jorda M, Morales C, Muñoz M, Vendrell E et al. Genome-wide tracking of unmethylated DNA Alu repeats in normal and cancer cells. Nucleic Acids Res 2008; 36: 770-784.
48. Phokaew C, Kowudtitham S, Subbalekha K, Shuangshoti S, Mutirangura A. LINE-1 methylation patterns of different loci in normal and cancerous cells. Nucleic Acids Res 2008; 14: 5704-5712.
49. Feinberg AP. The epigenetics of cancer etiology. Semin Cancer Biol 2004; 14: 427-432.
50. Chen RZ, Pettersson U, Beard C, Jackson-Grusby L, Jaenisch R. DNA hypomethylation leads to elevated mutation rates. Nature 1998; 395: 89-93.
51. Esteller M. Cancer epigenomics: DNA methylomes and histone modification maps. Nat Rev Genet 2007; 8: 286-298.
52. Dunn BK. Hypomethylation: one side of a larger picture. Ann N Y Acad Sci 2003; 983: 28-42.
53. Eden A, Gaudet F, Waghmare A, Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003; 300: 455.
54. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31: 27-36.
55. Chalitchagorn K, Shuangshoti S, Hourpai N, Kongruttanachok N, Tangkijvanich P, Thong-ngam D et al. Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis. Oncogene 2004; 23: 8841-8846.
56. Bedford MT, van Helden PD. Hypomethylation of DNA in pathological conditions of the human prostate. Cancer Res 1987; 47: 5274-5276.
57. Chin SP, Dickinson JL, Holloway AF. Epigenetic regulation of prostate cancer. Clin Epigenet 2010; 2: 151-169.
58. Wild L, Flanagan JM. Genome-wide hypomethylation in cancer may be a passive consequence of transformation. Biochim Biophys Acta 2010; 1806: 50-57.
59. Poole C, Greenland S, Luetters C, Kelsey JL, Mezei G. Socioeconomic status and childhood leukemia: a review. Int J Epidemiol 2006; 35: 370-384.
60. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to Meta-Analysis. Wiley: Chichester, 2009.
61. Whitlock MC. Combining probability from independent tests: the weighted Z-method is superior to Fisher's approach. J Evol Biol 2005; 18: 1368-1373.
62. Yegnasubramanian S, Haffner MC, Zhang Y, Gurel B, Cornish TC, Wu Z et al. DNA hypomethylation arises later in prostate cancer progression than CpG island hypermethylation and contributes to metastatic tumor heterogeneity. Cancer Res 2008; 68: 8954-8967.
63. Santourlidis S, Florl A, Ackermann R, Wirtz HC, Schulz WA. High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. Prostate 1999; 39: 166-174.
64. Schulz WA, Elo JP, Florl AR, Pennanen S, Santourlidis S, Engers R et al. Genome-wide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromosomes Cancer 2002; 35: 58-65.
65. Brothman AR, Swanson G, Maxwell TM, Cui J, Murphy KJ, Herrick J et al. Global hypomethylation is common in prostate cancer cells: a quantitative predictor for clinical outcome? Cancer Genet Cytogenet 2005; 156: 31-36.
66. Kindich R, Florl AR, Kamradt J, Lehmann J, Muller M, Wullich B et al. Relationship of NKX3.1 and MYC gene copy number ratio and DNA hypomethylation to prostate carcinoma stage. Eur Urol 2006; 49: 169-175.
67. Cho NY, Kim BH, Choi M, Yoo EJ, Moon KC, Cho YM et al. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol 2007; 211: 269-277.
68. Cho NY, Kim JH, Moon KC, Kang GH. Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm. Virchows Arch 2009; 454: 17-23.
69. Yang B, Sun H, Lin W, Hou W, Li H, Zhang L et al. Evaluation of global DNA hypomethylation in human prostate cancer and prostatic intraepithelial neoplasm tissues by immunohistochemistry. Urol Oncol 2013; 31: 628-634.
70. Kim JH, Dhanasekaran SM, Prensner JR, Cao X, Robinson D, Kalyana-Sundaram S et al. Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res 2011; 21: 1028-1041.
71. Mohamed MA, Greif PA, Diamond J, Sharaf O, Maxwell P, Montironi R et al. Epigenetic events, remodelling enzymes and their relationship to chromatin organization in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. BJU Int 2007; 99: 908-915.
72. Stanzer S, Balic M, Strutz J, Heitzer E, Obermair F, Hauser-Kronberger C et al. Rapid and reliable detection of LINE-1 hypomethylation using high-resolution melting analysis. Clin Biochem 2010; 13: 1443-1448.
73. Haffner MC, Chaux A, Meeker AK, Esopi DM, Gerber J, Pellakuru LG et al. Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers. Oncotarget 2011; 2: 627-637.
74. Lisanti S, Omar WAW, Tomaszewski B, De Prins S, Jacobs G, Koppen G et al. Comparison of methods for quantification of global DNA methylation in human cells and tissues. PLoS One 2013; 8: e79044.
75. Enokida H, Shiina H, Urakami S, Terashima M, Ogishima T, Li LC et al. Smoking influences aberrant CpG hypermethylation of multiple genes in human prostate carcinoma. Cancer 2006; 106: 79-86.
76. Zeilinger S, Kühnel B, Klopp N, Baurecht H, Kleinschmidt A, Gieger C et al. Tobacco smoking leads to extensive genome-wide changes in DNA methylation. PLoS One 2013; 8: e63812.
77. Enokida H, Shiina H, Urakami S, Igawa M, Ogishima T, Pookot D et al. Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer. Int J Cancer 2005; 116: 174-181.
78. Wallace TA, Martin DN, Ambs S. Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. Carcinogenesis 2011; 32: 1107-1121.
79. Greenland S, O'Rourke K. Meta-analysis. In: Rothman KJ, Greenland S, Lash TL (eds) Modern Epidemiology, 3rd edn. Lippincott-Williams and Wilkins: Philadelphia, 2008, pp 652-682.